Welcome to our dedicated page for Lilly Eli & news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & stock.
Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
The FDA has approved OLUMIANT (baricitinib), marking it as the first and only JAK inhibitor authorized for treating hospitalized adults with COVID-19 requiring oxygen support. Recommended dosing is 4 mg once daily for up to 14 days. This approval is based on positive results from Phase 3 studies ACTT-2 and COV-BARRIER, where OLUMIANT showed effectiveness without new safety concerns. Approximately one million patients have already received OLUMIANT globally since its emergency use in November 2020. Caution is advised due to risks of serious infections and other severe adverse events.
Eli Lilly and Company (NYSE: LLY) has elected Dr. Mary Lynne Hedley to its Board of Directors, effective May 15, 2022. Dr. Hedley, an expert in immunology and oncology, brings extensive experience from her roles at the Broad Institute and TESARO, a biotech firm she co-founded. She will serve on the Science & Technology Committee and the Ethics and Compliance Committee. CEO David A. Ricks expressed optimism about her addition, highlighting her leadership and technological insights as vital to Lilly's ongoing innovation and growth in the pharmaceutical industry.
Eli Lilly and Company (NYSE: LLY) will attend the Bank of America Securities 2022 Healthcare Conference on May 10-11, 2022. Daniel Skovronsky, M.D., Ph.D., will participate in a fireside chat on May 10 at 7:40 p.m. ET. A live audio webcast will be accessible on Lilly's Investor website, with a replay available for 90 days. Lilly aims to advance health through innovative therapies, impacting over 47 million people worldwide. For more details, visit Lilly's Investor site.
Eli Lilly and Company (NYSE: LLY) has declared a $0.98 dividend per share for the second quarter of 2022. This dividend is payable on June 10, 2022, to shareholders of record by May 16, 2022. The company focuses on innovative treatments for significant health challenges impacting millions globally. Lilly’s commitment includes enhancing accessibility and affordability of its medicines, and it has been pioneering advancements for nearly 150 years.
IgGenix, a biotechnology firm focused on alleviating allergic diseases, announces its move to Lilly Gateway Labs in South San Francisco, CA. This relocation aims to foster collaborations for scientific breakthroughs in allergy treatments. With over 50 million affected by allergies in the U.S., IgGenix intends to leverage its innovative single-cell discovery platform to develop safer therapeutic options. This partnership is expected to enhance access to Lilly's resources and expertise, ultimately addressing unmet treatment needs in the allergy space.
Eli Lilly reported a 15% revenue growth in Q1 2022, amounting to $7.81 billion, driven by a 20% volume increase. Excluding COVID-19 antibody revenues, growth was 10%. The company's key products contributed significantly, with Trulicity, Verzenio, and Jardiance driving most of the growth, representing 61% of core revenue. Reported EPS was $2.10, a 41% increase, with non-GAAP EPS at $2.62, up 63%. Updated EPS guidance for 2022 is $7.30 to $7.45 reported and $8.15 to $8.30 non-GAAP.
Eli Lilly's tirzepatide has shown significant results in the SURMOUNT-1 clinical trial, achieving up to 22.5% weight loss in participants over 72 weeks. The study, which involved 2,539 participants, indicated that 63% of those on the 15 mg dose lost at least 20% of their body weight. Tirzepatide met all co-primary and key secondary endpoints, and the safety profile was comparable to existing therapies. Adverse events were mostly mild to moderate, with gastrointestinal issues being common. Ongoing studies will further evaluate its long-term effects and potential diabetes progression.
Boehringer Ingelheim and Eli Lilly have launched Hear Your Heart, an initiative aimed at empowering women, particularly Black and Latina women, who are living with heart failure. Heart disease is the leading cause of death in the U.S., affecting over six million people, with women often facing worse outcomes compared to men. The program provides tailored resources and education to help women prioritize their care, address health disparities, and optimize heart failure management. This initiative underscores the importance of equitable healthcare for this underserved population.
Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2022 financial results on April 28, 2022. Following this, the company will hold a conference call at 9 a.m. Eastern time to discuss the financial performance with investors and media. A live webcast will be available on Lilly's official website, along with a replay post-call. Lilly has a significant history of impacting global health with its innovative medicines, which help over 47 million people worldwide.
Lilly's lebrikizumab, an investigational IL-13 inhibitor, showed significant promise in treating moderate-to-severe atopic dermatitis (AD) in the ADhere trial. At 16 weeks, 70% of patients treated with lebrikizumab and topical corticosteroids (TCS) achieved EASI-75, compared to 42% with placebo. Improvements were noted in skin clearance, itch, sleep, and quality of life. Safety profiles were consistent with previous studies, with mild adverse events reported. Lilly seeks to advance lebrikizumab globally after receiving Fast Track designation from the FDA.